#ai-drug-discovery
#ai-drug-discovery

[ follow ]

#startup-funding #antibody-design #nyc-startups #insurtech #pharma-partnerships #seed-funding

fromSouth China Morning Post

HKTDC programme supports overseas start-ups' Asian market entry

Companies prioritize Hong Kong and Greater Bay Area access for early Asian expansion, especially health-tech and advanced manufacturing targeting clinical and commercial markets.

Daily briefing: Why we enjoy things more when they're hard to get

According to a new analysis, about 55% of the observed variation in longevity across a population is attributable to genetics - challenging previous estimates of 10-25%. Researchers say that earlier numbers were much too low because they did not effectively separate deaths caused by extrinsic factors, such as accidents, from intrinsic ones such as the gradual decline of organ function. Not all intrinsic causes of death are equally heritable, the researchers found - and the results don't indicate a genetically encoded 'destiny' for lifespan, because so much is determined by environment and lifestyle choices.

Science

Inside Big Pharma, VC's big bet on AI: 'We wouldn't fly in an airplane designed by hand, but all of our drugs are designed like that' | Fortune

AI-driven drug design aims to narrow the astronomical chemical search space and accelerate medicine development, backed by major funding and breakthroughs like AlphaFold.

AI drug startup Insilico Medicine launches an AI 'gym' to help models like GPT and Qwen be good at science | Fortune

Generalist models "fail miserably" at the benchmarks used to measure how AI performs scientific tasks, Alex Zhavoronkov, Insilico's founder and CEO, told Fortune. " You test it five times at the same task, and you can see that it's so far from state of the art...It's basically worse than random. It's complete garbage." Far better are specialist AI models that are trained directly on chemistry or biology data.

Science

#startup-funding

New York City

#NYCtech Week in Review: 1/11/26 - 1/17/26

NYC startups secured major funding this week, led by Rain ($250M), Proxima ($80M), WithCoverage ($42M), Flip CX ($20M), GiveCard ($8.9M), Noise Labs ($7.1M).

NYC startup

#NYCtech Week in Review: 5/4/25 - 5/10/25

Several NYC startups secured significant funding in recent news, indicating a robust ecosystem.

Wonder raised $600M, leading the funding round among several successful startups.

New York City

#NYCtech Week in Review: 1/11/26 - 1/17/26

#NYCtech Week in Review: 5/4/25 - 5/10/25

Several NYC startups secured significant funding in recent news, indicating a robust ecosystem.

Wonder raised $600M, leading the funding round among several successful startups.

more#startup-funding

#antibody-design

Medicine

From OpenAI's offices to a deal with Eli Lilly - how Chai Discovery became one of the flashiest names in AI drug development | TechCrunch

Startup companies

OpenAI-backed biotech firm Chai Discovery raises $130M Series B at $1.3B valuation | TechCrunch

Medicine

From OpenAI's offices to a deal with Eli Lilly - how Chai Discovery became one of the flashiest names in AI drug development | TechCrunch

Startup companies

OpenAI-backed biotech firm Chai Discovery raises $130M Series B at $1.3B valuation | TechCrunch

more#antibody-design

The AlleyWatch Startup Daily Funding Report: 1/14/2026

Proxima raised $80M Seed for AI-driven proximity-based drug discovery; WithCoverage raised $42M Series B for risk management and insurance brokerage for fast-growing businesses.

#antibiotic-resistance

fromFast Company

Artificial intelligence

What will define 2026, according to leaders in space, healthcare, and AI

fromFast Company

Medicine

MIT drug hunters are using AI to design completely new antibiotics

fromFast Company

Artificial intelligence

What will define 2026, according to leaders in space, healthcare, and AI

fromFast Company

Medicine

MIT drug hunters are using AI to design completely new antibiotics

more#antibiotic-resistance

Converge Bio raises $25M, backed by Bessemer and execs from Meta, OpenAI, Wiz | TechCrunch

Generative AI trained on DNA, RNA, and protein sequences accelerates drug discovery, enabling faster antibody design, protein optimization, and target identification while attracting investor funding.

from24/7 Wall St.

Eli Lilly and Nvidia Make $1 Billion AI Bet to Revolutionize Pharma's Future

Eli Lilly and Nvidia will invest up to $1 billion in a five-year AI co-innovation lab to accelerate drug discovery using machine learning and supercomputing.

#NYCtech Week in Review: 11/30/25 - 12/5/25

Multiple NYC startups secured significant venture funding, led by Eon ($300M), Excelsior Sciences ($70M), PermitFlow ($54M), Fin ($17M), and IMTC ($12M).

The World

Saudi crown prince met President Trump; Peru seeks to curb mercury in small-scale gold mining; UK uses AI to fast-track antibiotics; Winter Olympics entry questioned.

Longevity science is on the cusp of major breakthroughs thanks to AI, but significant 'data gaps' need to be filled, expert says | Fortune

Data is the key. The depth of biological data, the depth of demographical data, the depth of epidemiological data has to be properly collected,

Artificial intelligence

Artificial intelligence

This AI method could turbocharge the hunt for new medicines

An AI model trained on cellular genomic perturbation data can accelerate drug discovery by predicting compound effects across cell types, reducing costly large-scale screens.

fromSilicon Canals

Belfast-based AMPLY Discovery completes 1.5M seed funding

AMPLY Discovery raised $1.75M to develop innovative AI-driven drug discovery therapies targeting cancers and drug-resistant infections in preclinical stages.

[ Load more ]